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Abstract 
This study evaluated thermoplastic polyurethanes (TPUR) as matrix excipients for the production 
of oral solid dosage forms via hot melt extrusion (HME) in combination with injection molding 
(IM). We demonstrated that TPURs enable the production of solid dispersions – crystalline API 
in a crystalline carrier – at an extrusion temperature below the drug melting temperature (Tm) 
with a drug content up to 65% (wt.%). The release of metoprolol tartrate was controlled over 24h, 
whereas a complete release of diprophylline was only possible in combination with a drug release 
modifier: polyethylene glycol 4000 (PEG 4000) or Tween 80. No burst release nor a change in 
tablet size and geometry was detected for any of the formulations after dissolution testing. The 
total matrix porosity increased gradually upon drug release. Oral administration of TPUR did not 
affect the GI ecosystem (pH, bacterial count, short chain fatty acids), monitored via the Simulator 
of the Human Intestinal Microbial Ecosystem (SHIME). The high drug load (65wt.%) in 
combination with (in-vitro and in-vivo) controlled release capacity of the formulations, is 
noteworthy in the field of formulations produced via HME/IM. 
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Introduction 
Sustaining drug release from a dosage form after oral administration offers distinct 
advantages to chronic and poly-medicated patients: maintaining drug levels in the therapeutic 
range, lower dosing frequency, less side effects; resulting in a better patient compliance. While 
sustained drug release can be achieved based on the design of the dosage form (reservoir systems 
vs. matrices) and/or the physicochemical properties of the polymeric materials incorporated in the 
formulation (diffusion controlled vs. delayed polymer dissolution), hot melt extrusion (HME) 
(possibly in combination with injection molding) has been evaluated to manufacture sustained-
release matrices using various polymers: ethylcellulose (EC) [1-3], hydroxypropyl (methyl) 
cellulose (HP(M)C) [4], ethylene vinyl acetate (EVA) [5-6], polyvinyl acetate (PVA) [7], poly 
lactic (co-glycolic) acid (PL(G)A) [8-9], silicone [10], polycaprolactone (PCL) [11-12], 
polyoxazolines [13], polyanhydrides [14], methacrylate copolymers (Eudragit® RS/RL) [15-16], 
and several lipid materials [17-19]. While sustained-release dosage forms have been successfully 
developed via HME using these polymers, a common drawback is that the drug load in these 
formulations is often low, either linked to processing issues during HME of formulations with a 
high drug load, or due to a significant burst release when less polymeric matrix former is 
incorporated in the formulation. Quinten et. al. [20], for instance, described that drug load in an 
acrylic polymermatrix was limited to 30% when processed via HME/IM, drug release from these 
matrices occurred in a first order manner via a combination of swelling and diffusion. Reitz et al. 
managed [21] to produce extrudates with 65wt.% diprophylline via solid lipid extrusion (with 
glycerol trimyristate as carrier) and identified the importance of drug particle size: although a 
larger drug particle size reduced the release rate and minimized the burst release, sustained 
release from these high dosed lipid matrices was limited (70% drug release after 1 and 3 h for 
small and large drug particle sizes, respectively). Another study [22] incorporated 30wt.% 
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diprophylline in Eudragit® S100 and Eudragit® L matrices, processed via HME at 160°C, and due 
to the complete dissolution of diprophylline in the matrix poor sustained release properties 
(>50% released within 2h in 1N HCl) were registered. It is well documented that a higher drug 
load enhanced the release rate from the matrix since more pores are created in the micro-capillary 
network of the insoluble matrix upon drug release, often combined with a burst release. To this 
end, the design of novel sustained release dosage forms using innovative polymeric materials 
with improved characteristics for controlled drug release is continuously under investigation. 
Thermoplastic polyurethanes (TPUR) are inert, non-ionic, water-insoluble polymers that 
have been successfully used for many years as drug release controlling polymers in vaginal rings 
[23-25], stents [26], coatings [27] and implants [28]. Another important application of TPUR is in 
medical tubing as its superior mechanical properties (compared to polyvinyl chloride) allow the 
use of thinner walled tubes, even without a plasticizer [29]. The chemical structure of TPUR 
consists of alternating hard segments (HS) in a continuous phase of soft segments (SS)  
(Figure 1). Typically the SS phase is composed of a relatively long, flexible polyester or 
polyethers with a molecular weight of 1000-10.000g/mol. The HS can be composed of linear 
4,4’-methylene diphenyl diisocyanate (MDI) or its hydrogenated form (HMDI), possibly linked 
to one another via a chain extender (often short chain diols). Thermodynamic incompatibility of 
both segments results to a certain degree of insolubility between HS and SS, yielding a 
microphase-separated (segmented) polymer. This generates a polymer with unique 
physicochemical characteristics: an elastomeric material with superior tensile strength, abrasion 
resistance, crack resistance, inherent lubricity and biocompatibility [30]. To this end, the HS 
contributes to the polymers’ strength due to the formation of intermolecular hydrogen bonds 
between the urethane structures (NH-(C=O)-O) in each HS, while the SS fraction with a low 
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glass transition temperature (Tg) provides the polymers’ elasticity [31]. TPUR are available in 
various molecular weights, different types (polyester, polyether) of SS, different SS lengths, and 
variable SS/HS ratios which makes them attractive candidates to alter drug release performances 
based on polymer composition.  
In this study, we evaluated thermoplastic polyurethanes (TPUR) as matrix excipients for 
oral sustained release purposes. The formulations were produced via hot-melt extrusion followed 
by injection molding and were consequently (physicochemically) characterized. Metoprolol 
tartrate (MPT), theophylline (Th) and diprophylline (Dyph) were embedded as model drugs in the 
TPUR matrices. 
In addition to the processing of TPUR via hot-melt extrusion and its physicochemical 
evaluation, an assessment of the safety of TPUR upon oral intake was performed via the SHIME 
(Simulator Human Intestinal Microbial Ecosystem) study. While this approach does not provide 
an entire toxicological report, it can give a first impression about the impact of the gastro-
intestinal fluids on the integrity of TPUR and the effect of TPUR on the microbial flora. Upon 
oral intake, the formulation passes the intestinal environment where chemical and/or enzymatic 
reactions can affect the polymer structure. Also, the human colon, which is colonized by a 
complex microbial community, can modify the polymer structure and may in turn be influenced 
by exposure to the polymer. 
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Experimental Section  
Materials 
Various grades of TPUR (Table 1) with varying composition of the hard and soft 
segments and with variable SS/HS ratio (Table 1) were obtained from Merquinsa (a Lubrizol 
company, Ohio, USA): the Pearlbond polyurethanes (P520, P522, P523, P539) were non-medical 
grades, while the Tecoflex types (T85A, T100A, T72D) were medical grades (Figure 2). 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain), theophylline (Th) and 
diprophylline (Dyph, 7-(2,3-dihydroxypropyl)-theophylline) (Sigma Aldrich, Bornem, Belgium) 
are embedded as model drugs in the TPUR matrices. Polyethylene glycol 4000 and Tween 80 
were obtained from Fagron (Waregem, Belgium). 
 
Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) was performed on a Waters instrument, equipped 
with 3 serial Polymer Standards Services columns (1 x GRAM Analytical 30 Å and 2 x GRAM 
Analytical 1000 Å, 10 µm particle size) at 35°C. Poly(methylmethacrylate) (PMMA) standards 
were used for calibration and dimethylacetamide (DMA), containing LiBr (0.42 g/mL) to 
increase polymer solubility, was used as solvent at a flow rate of 1 mL/min. 100 µL of a 10 
mg/mL TPUR solution was injected onto the column. TPUR in the eluent was detected using 
a Waters 2414 refractive index detector. Molecular weights were determined using the Empower 
software (Waters, Zellik, Belgium). 
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Nuclear magnetic resonance (NMR) 
NMR spectra were recorded on a Bruker AVANCE 300 spectrometer, using deuterated 
dimethylformamide (DMF) as solvent, to determine the polymer structure and SS/HS ratio. The 
spectra were analyzed with the ACD/Spec Manager software from ACD/Labs. 1H-NMR (300 
MHz, DMF-d7) of Pearlbond polymers: δ (ppm) = 1.37 (m, CH2-CH2-CH2-O), 1.61 (m, CH2-
CH2-CH2-O), 2.33 (t, CH2-CH2-CH2-(CO)), 3.86 (s, Ph-CH2-Ph), 4.05 (t, CH2-CH2-CH2-O), 7.17 
(d, aromatic), 7.48 (d, aromatic), 9.45 (s, O(CO)NH). 1H-NMR (300 MHz, DMF-d7) of Tecoflex 
polymers: δ (ppm) = 0.86 – 1.88 (br, CH2 cyclic and CH2-CH2-O(CO)NH), 1.57 (br, CH2 
backbone pTHF), 3.39 (br, CH2-O), 3.62 (br, O(CO)NH-CH), 3.98 (br, CH2-CH2-O(CO)NH), 
6.71-7.03 (br, O(CO)NH). 
Fourier-transform infrared spectroscopy 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 
performed on the polymers before and after the SHIME-experiment in order to identify molecular 
changes. Spectra were recorded using a Nicolet iS5 ATR FT-IR spectrometer (Thermo Fisher 
Scientific). A diamond ATR crystal was pressed against the samples. Each spectrum was 
collected in the 4000 - 550 cm-1 range with a resolution of 2 cm-1 and averaged over 32 scans. 
Thermal analysis 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was used to 
investigate the thermal stability of the polymers. The samples were equilibrated at 30°C and 
heated (10°C/min) to 500°C under an N2 atmosphere.  
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The glass transition temperature (Tg) and melting point (Tm) of pure components, 
physical mixtures and injection molded tablets were analyzed in Tzero pans (TA instruments, 
Zellik, Belgium) by modulated differential scanning calorimetry (MDSC Q2000, TA Instruments, 
Leatherhead, UK) using a heating rate of 2°C/min. The modulation period and amplitude were set 
at 1min and 0.318°C, respectively (heat-iso method). Dry nitrogen at a flow rate of 50mL/min 
was used to purge the MDSC cell. Analysis of the thermal characteristics (Tm, and Tg) was done 
via a heating/cool/heat run between -70°C and 75°C and between -70°C and 140°C for the 
physical mixtures with Pearlbond and Tecoflex polymers, respectively. The melting enthalpy (in 
the total heat flow signal), Tmelt-max (i.e. inflection point of melting endotherm) and Tmelt-
onset (i.e. start of melting endotherm) were analyzed in the first heating cycle. The crystallinity 
was determined by dividing the API melting enthalpy in the formulation by the melting enthalpy 
of pure API components (=100% crystalline). Analysis of the glass transition temperature was 
done in the first and second heating cycle for injection molded tablets and physical mixtures, 
respectively. All results were analyzed using the TA Instruments Universal Analysis 2000 
software. 
Production of injection molded tablets 
Physical mixtures, homogenized using mortar and pestle, of drug/polymer at a ratio of 
50/50, 65/35 and 75/25 were extruded at 70°C for MPT-containing formulations, and at 140°C 
for Th- and Dyph-containing formulations using a lab-scale co-rotating twin-screw extruder at 
100rpm (Haake MiniLab II Micro Compounder, Thermo Electron, Karlsruhe, Germany). The 
mixtures were manually fed into the extruder in order to avoid segregation due to differences in 
particle size between API (µm range) and TPUR (mm range). Immediately after HME, the 
thermoplastic melt was processed into biconvex tablets (diameter: 10mm/height: 5mm) via 
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injection molding (Haake MiniJet System, Thermo Electron). The injection pressure was 800bar 
during 10s, in combination with a post-pressure of 400bar for 5s. The temperature during 
injection molding was the same as during HME: 70 and 140°C for MPT-containing and Th- and 
Dyph-containing formulations, respectively. 
Raman mapping 
The homogeneity of the distribution of MPT in the tablets was evaluated by Raman 
microscopic mapping using a Raman Rxn1 Microprobe (Kaiser Optical Systems, Ann Arbor, MI, 
USA) equipped with an air-cooled CCD detector. The laser wavelength employed was a 785 nm 
from a Invictus NIR diode laser. The tablet surface was scanned by a 10x long working distance 
objective lens (spot size 50 μm) in area mapping mode using an exposure time of 4s and a step 
size of 50 μm in both the x (18 points) and y (13 points) direction (=234 spectra or 850 x 600µm 
per mapping segment). Six areas were analyzed in total. Data collection and data transfer were 
automated using HoloGRAMS™ data collection software (version 2.3.5, Kaiser Optical 
Systems), the HoloMAP™ data analysis software (version 2.3.5, Kaiser Optical Systems) and 
Matlab® software (version 7.1, The MathWorks, Natick, MA, USA). All spectra were reduced to 
800-1500cm-1, a spectral range which contains the fingerprint region of both components. The 
spectra were baseline corrected using Pearson’s method and then normalized. 
 
The 234 Raman spectra collected per monitored area were each introduced into a data 
matrix (D), resulting in a Raman data matrix per area. Each D was analyzed using multivariate 
curve resolution (MCR). MCR aims to obtain a clear description of the contribution of each pure 
component in the area from the overall measured variation in D. Hence, all collected spectra in 
the area are considered as the result of the additive contribution of all pure components involved 
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in the area. Therefore, MCR decomposes D into the contributions linked to each of the pure 
components in the system: 
D = CS + E           (equation 1) 
where C and S represent the concentration profiles and spectra, respectively. E is the error 
matrix, which is the residual variation of the dataset that is not related to any chemical 
contribution. Next, the working procedure of the resolution method started with the initial 
estimation of C and S and continued by optimizing iteratively the concentration and response 
profiles using the available information about the system. The introduction of this information 
was carried out through the implementation of constraints. Constraints are mathematical or 
chemical properties systematically fulfilled by the whole system or by some of its pure 
contributions. The constraint used for this study was the default assumption of non-negativity; 
that is, the data were decomposed as non-negative concentration times non-negative spectra [32]. 
Melt rheology 
 Melt rheology of TPUR was determined using an Anton Paar MCR301 (Oregon, USA) 
rheometer. The gap between plate spindle (diameter 25 mm) and plate was 1 mm. The strain 
amplitude and the angular frequency used were 1% and 10 rad/s, respectively. The Pearlbond and 
Tecoflex viscosities were measured at a temperature of 70 and 140°C, respectively.  
Scanning electronic microscopy 
IM tablets were sputtered with platinum using the JEOL JFC 1300 Auto Fine Coater 
(Jeol, Zaventem, Belgium). The samples were examined with a JEOL JSM 5600 LV scanning 
electron microscope (Jeol) at a magnification of 1000x.  
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He pycnometry 
The tablet porosity was calculated based on the difference between the bulk and skeletal 
volume of the injection molded tablets. The skeletal volume of the tablets was measured (at 
different time points during dissolution experiments: 2, 4, 6, 8 and 24 h) via He pycnometry 
(AccuPyc 1330, Micromeritics, Norcross, USA). Prior to He pycnometry the tablets were dried 
for 2 days at 30°C. As no shrinkage or swelling of the injection molded tablets was observed 
immediately after injection molding nor after 24 h dissolution testing (verified by measuring 
tablet diameter and height using a digital slide caliper), the bulk volume of the tablets was 
determined from the dimensions of the mold. The tablet porosity () was calculated based on the 
following equation: 
 = [ (bulk volume – skeletal volume)/bulk volume ] x 100           
(equation 2) 
In vitro drug release 
Drug release from the injection molded tablets was determined using the paddle method 
on a VK 7010 dissolution system (VanKel Industries, New Jersey, USA) with a paddle speed of 
100rpm. Distilled water was used as dissolution medium (900mL) at 37 ± 0.5°C. Samples were 
withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and spectrophotometrically analyzed for API 
concentration at 272nm for Th and 274nm for MPT and Dyph, respectively. 
In vivo evaluation  
All procedures were performed in accordance with the guidelines and after approval by 
the Ethics Committee of the Faculty of Veterinary Medicine (Ghent University). To study the 
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influence of MPT concentration, 2 formulations were administrated to 6 dogs: (a) formulation F1:  
IM tablets containing 65 % MPT and 35 % Pearlbond 539 (equivalent to 239mg MPT), (b) 
formulation F2 (reference): Slow-Lopresor® 200 Divitabs® (Sankyo, Louvain-la-Neuve, 
Belgium), a commercial sustained release formulation consisting of matrix tablets containing 200 
mg MPT. 
 
All formulations were administrated to 6 male mixed-breed dogs (10 – 13 kg) in a cross-
over study with a wash-out period of at least 8 days. Since the size of the molded tablets was 
fixed, different MPT doses (239 and 200 mg for F1 and F2, respectively) were administered. The 
pharmacokinetic profiles were normalized as linear pharmacokinetics have been reported for 
MPT in a dose range between 50 and 400 mg [33]. The dogs were fasted 12 h prior to 
administration and 12 h after administration, although water was available ad libitum. Before 
administration, an intravenous cannula was placed in the lateral saphenous and a blank blood 
sample was collected. The formulations were administrated with 20 mL water, and blood samples 
were collected in dry heparinized tubes at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h after 
administration. The obtained blood samples were centrifuged at 1500g during 5 min. A validated 
HPLC method [34] with fluorescence detection was used for the determination of MPT in dog 
plasma. The peak plasma concentration (Cmax) and the time needed to reach the highest plasma 
concentration (tmax) were determined. The controlled release characteristics of the formulations 
were evaluated by means of the HVDt50%Cmax defined by the period during which the plasma 
concentration exceeds 50 % of Cmax [35-36]. The intact tablets, collected in the faeces of the 
dogs, were analyzed for their remaining MPT concentration. These tablets were crushed using 
mortar and pestle, suspended in 100mL demi water for 24 h and the MPT concentration in the 
supernatant was spectrophotometrically analyzed at 274nm. 
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Simulator of the Human Intestinal Microbial Ecosystem (SHIME)  
The stability of TPUR grades T85A and P523 upon oral ingestion was evaluated in the 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME), developed by the Laboratory 
of Microbial Ecology and Technology, Ghent University, as described earlier [37]. In brief, both 
polymers (2 g/l) were added to a standardized nutritional medium and incubated under simulated 
stomach conditions for 90 min (37°C, aerophilic conditions). Next, an appropriate amount of bile 
salts and digestive enzymes was added to simulate small intestinal conditions, and the samples 
were further incubated for 150 min (37°C, microaerophilic conditions). Finally, a complex 
microbial community was taken from the ascending colon compartment of the SHIME and added 
to the setup. The samples were further incubated for a period of 48 h (37°C, anaerobic 
conditions). All experiments were performed in triplicate. As a control, the same experiment was 
performed in parallel, without addition of TPUR. Both polymers were isolated from the stomach, 
small intestinal and colon incubation medium, and the polymer’s integrity and structure was 
analyzed by means of MDSC and FTIR. The potential breakdown of the polymer by the intestinal 
microflora was indirectly assessed. Changes in composition or activity of the microbial 
community in the test with TPUR as compared to the control were used as marker for interaction 
between TPUR and the intestinal microbiota. Changes in composition were assessed by selective 
plate counting for different bacterial groups, as described by Possemiers et al. [38]. Effects on 
microbial activity were evaluated by pH measurements and by quantification of the 
concentrations of shortchain fatty acids (SCFA) in the samples at the beginning and end of the 
colonic incubations, as described earlier [38]. 
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Results and Discussion 
Processability via extrusion and injection molding 
Initially, the maximum drug load of the formulations that allowed processing via HME 
and IM was determined. Using Pearlbond and Tecoflex polymers as matrix formers, two distinct 
factors were negatively influencing the production of high drug load matrices: processing 
temperature and powder fraction in the formulation. If the processing temperature exceeded the 
API’s melting point (Tm), HME processing became impossible at high drug loads as the matrix 
former was not able to absorb the large amount of molten API, resulting in a too liquid phase 
without the plasticity required for the HME process. In addition, a large powder fraction in a 
formulation also compromised HME processing below the API’s Tm as the high percentage of 
crystalline API resulted in a too high torque during HME. Therefore, the TPUR fraction in the 
formulation must be sufficient to provide sufficient plasticity during thermal processing. 
Thermal processing of Pearlbond polymers was possible at a temperature of 70°C. 
Polycaprolactone (PCL, (C6H10O2)n), the semi-crystalline polyester soft segment (SS) in 
Pearlbond, has a Tg of around -60°C and melts at 55°C [39]. The combination of hard segments 
(HS), intermolecular connected via H-bonds, and the molten SS provides the polymer with 
sufficient plasticity needed for the extrusion process. This low processing temperature enabled 
the production of high drug loaded formulations with all three API’s: MPT, Dyph and Th (Tm of 
120, 160 and 270°C, respectively). The maximum drug load was 65wt.% API using P523 and 
P539 as matrix formers, while only 50wt.% API could be combined with P520 and P522. This 
difference in processability was correlated with the lower SS/HS ratios of P520 and P522  
(Table 1). A higher fraction of hard segment (HS), methylene diphenyl diisocyanate (MDI) in 
Pearlbond, hampers the movement of SS, which makes the polymer more rigid and, hence, more 
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difficult to process. Thermal analysis confirmed this increase in rigidity as the change in heat 
capacity (∆Cp) at the Tg of P539, P523 and P520 was inversely correlated to the SS/HS ratio 
(Figure 3): a higher fraction of HS in TPUR increased the energy needed to transform the 
polymer from its glass state to a rubbery phase, reducing the processability of P520. These 
findings were also confirmed by melt rheology experiments of the polymers, as higher melt 
viscosities were measured at 70°C for P520 and P522, respectively (Table 1). The polymer melt 
viscosity could be correlated with their extrusion processability as the API did not dissolve in the 
polymer melt during HME/IM processing: no loss of API crystallinity was detected in the IM 
tablets based on the melting enthalpy of an MPT/P539 formulation containing 50 and 65% drug, 
corresponding to 99 and 100% MPT crystallinity, respectively. Similar results were obtained 
when the other Pearlbond/drug combinations were processed (data not shown). 
The formulations based on the medical grade polyether TPUR (Tecoflex) could only be 
processed via extrusion and injection molding at a temperature of 140°C. This higher energy 
input, required for the Tecoflex polymers to provide sufficient plasticity to the formulation, is 
most likely linked to their chemical structure consisting of hydrogenated MDI (HMDI) as HS 
with a shorter and thus more rigid poly-tetrahydrofuran (pTHF, (C4H8O)n) as SS [40]. They also 
contain a chain extender, most likely a butanediol, which increases the HS length, a significantly 
lower SS/HS ratio (Table 1) and a higher polymer melt viscosity. The higher processing 
temperature, however, excluded MPT from Tecoflex-based formulations as its melting point (Tm: 
120°C) was below the process temperature, yielding a liquid mixture without the 
(thermo)plasticity required for HME. Using T85A and T100A as matrix former, formulations 
were produced up to an API content of 65wt.%, while even a drug load of 75wt.% was possible 
in combination with T72D. Processing of Dyph/Tecoflex mixtures at high drug load via HME 
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and IM was facilitated by the partial loss of Dyph crystallinity during HME: at a drug load of 65 
wt%. in T72D and T100A matrices 63 and 70%, respectively, of crystalline Dyph was recovered 
in the IM tablets.  
An additional advantage of TPUR is its inherent lubricity [30]. Previous studies 
considering the injection molding technique used a silicon-based anti-sticking spray to facilitate 
the release of the solidified tablets from the mold [2, 41] or had problems with the brittleness of 
their formulations [13, 42]. Using TPUR as matrix former, no sticking to the mold was observed, 
nor brittleness of the matrix after cooling.  
In-vitro drug release 
The influence of drug load on the release is illustrated in Figure 4A. By incorporating 50, 
60 and 65wt.% MPT in the TPUR matrix, the release after 24h is 33, 66 and 100%, respectively. 
These findings can be correlated to the percolation theory [43-44] as a minimum amount of MPT 
(percolation threshold) is needed to generate sufficient pores in the inert TPUR matrix in order to 
ensure sufficient diffusional channels throughout the entire matrix allowing dissolution and 
release of the entire drug content. Diffusional mass transport (and eventually limited drug 
solubility effects) can be expected to play an important role in the control of drug release from 
the TPUR matrices. No changes in tablet dimensions (diameter/height) and tablet geometry 
(biconvex tablets) were observed for any of the formulations: no swelling or erosion occurred 
upon wetting of the TPUR matrices. At constant drug load, the drug release profiles were 
independent of the TPUR grade incorporated in the formulation (data not shown). Figure 4B 
illustrates the effect of drug solubility on the release profiles (at a 65wt.% drug load). While the 
highly soluble MPT (aqueous solubility >1000 mg/mL) ensures a complete release after 24h, the 
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release of Th (10mg/mL) and Dyph (333mg/mL) was, due to their lower aqueous solubility, 
limited to 20 and 50%, respectively. The addition of a pore former was required to ensure 
complete release of these drugs: Figure 4C and 4D represent the effect of PEG 4000 (hydrophilic 
substance) and Tween 80 (surfactant) on the release of Dyph. A gradual increase in drug release 
is observed in function of the amount of pore-former. The addition of PEG 4000 and Tween 80 to 
the formulation not only facilitated drug release from the TPUR matrices by generating extra 
diffusional channels for the API, it also enabled the production of matrices with a higher drug 
load (>65wt.%) as the melting of PEG 4000 and the liquid Tween 80 phase acted as a lubricant 
during HME/IM processing. A P539 formulation with a 70% MPT load and 10%  
PEG 4000 could be processed into high quality tablets; obviously this higher drug load 
compromised the sustained release capacities of the formulation (complete release already after 
12h, data not shown). In addition to the lubricating effect of the pore formers, the addition of 5 
and 10% Tween 80 to the formulation (Dyph/P539 65/35) reduced Dyph crystallinity to 76% and 
67%, respectively, thus lowering the rotational friction during HMEand improving processability. 
Similar results were obtained when PEG 4000 was used as pore-former (data not shown). Figure 
5 illustrates the correlation between tablet porosity and in-vitro drug release of a MPT/P539 
65/35 formulation: the dissolution of interconnecting drug clusters creates additional pores 
through which the remaining drug can dissolve, creating an empty porous TPUR matrix after 24 
h. The formation of additional pores during dissolution and the creation of an empty porous 
TPUR matrix was confirmed via AFM and SEM experiments (Figure 6). Prior to dissolution, 
needle-like MPT crystals were detected at the surface of the tablet, whereas after dissolution 
pores of approximately 10µm were observed.  
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Raman mapping  
To evaluate the distribution homogeneity of the crystalline API, Raman microscopic 
mapping was performed on the tablets. Six areas were mapped and each area was analyzed using 
MCR analysis to determine the true underlying factors contributing to the spectral variation. The 
spectral range studied (800-1500cm-1) contained the fingerprint region of both components of the 
formulation. No spectral difference was observed in any of the six evaluated area: crystalline API 
was homogeneously distributed at the surface of the tablet. 
Oral toxicity: Simulator human intestinal microbial ecosystem (SHIME) 
P523 and T85A (2g/l) were added to the SHIME system to determine its intestinal 
stability and its possible impact on microbial metabolism indicators (pH, short chain fatty acids 
[45] and bacteria). No significant differences were observed in bacterial count (Figure 7), short 
chain fatty acids and pH (data not shown). The polymer structure of T85A was not altered during 
gastro-intestinal transit as MDSC and FTIR showed similar thermal behavior and spectra, 
respectively. The structure of P523, on the other hand, was affected as the peaks at 1100, 1275 
and 1325cm-1 disappeared after exposure to the SHIME media. The first peak was linked to 
symmetrical ester stretch vibration [46], whereas the other two were assigned to chemical 
changes in the amorphous SS region of TPUR [46]. Previous research [47-48] already described 
that polyether-based polyurethanes are more resistant to biodegradation than polyester-based 
polyurethanes. This first toxicity screening of T85A revealed no evidence of chemical and/or 
enzymatic reaction after exposure to the intestinal environment, whereas P523 showed signs of 
ester linkage degradation/hydrolysis. This first indication, regarding TPUR toxicity upon oral 
administration, was considered positive as the activity or composition of the GI bacterial 
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community, the pH values and the presence of short chain fatty acids were not altered after 
exposure to both polymers.  
 
In-vivo evaluation 
Figure 8 illustrates the in vitro dissolution profiles and the mean plasma concentration-
time profiles after oral administration to beagle dogs of MPT tablets (polyurethane matrix, drug 
load 65wt.%) and the reference formulation (Slow-Lopresor® 200 Divitabs®, drug load 
47wt.%). In vitro dissolution yielded a complete release of MPT after 12 and 24 h for the 
reference and the polyurethane matrix, respectively. The reference formulation is subjected to 
surface erosion of its matrix allowing MPT to escape faster due to the increased surface area, 
while the tablet geometry of the polyurethane matrix remained unchanged after 24 h dissolution 
experiments. These differences between in vitro drug release patterns were also reflected in their 
in vivo behavior. Oral administration of the polyurethane formulation resulted in a lower Cmax 
and a more sustained release of MPT (up to 16 h) compared to the reference formulation (up to 
12 h). These differences in MPT plasma concentration, however, were not statistically 
significant. Moreover, intact TPUR tablets, which still contained 13% of their initial MPT 
content, were collected from the faeces of the dogs. No remnants of the reference formulation 
were found. This is probably attributed to the fast gastro-intestinal (GI) transit time in dogs in 
combination with a limited amount of fluids in the dog  [49], thereby limiting MPT dissolution 
from the polyurethane matrix. The reference formulation is, compared to the polyurethane matrix, 
less susceptible to the GI transit time and the limited fluids as surface erosion alters the surface 
area of the formulation. Other pharmacokinetic parameters (AUC, tmax and HVDt50%Cmax) did not 
differ significantly (p>0.05).  
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Conclusion 
This study demonstrated that TPUR polymers are promising matrix formers to produce 
oral controlled release formulations. Sustained release (in-vitro and in-vivo) of MPT, a highly 
water-soluble drug, was achieved, while diprophylline required a drug release modifier (Tween 80 
or PEG 4000). The high drug load in combination with controlled release capacities is 
noteworthy in the field of formulations produced via HME/IM. 
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